Telehealth has fundamentally changed how patients access obesity pharmacotherapy. A process that previously required a specialist referral — often with a months-long wait — can now be initiated from home and completed within 24–48 hours. That accessibility is genuinely valuable. It is also a double-edged development: the same frictionless access that connects appropriate candidates with effective therapy can, on poorly regulated platforms, move too fast past clinical safeguards that exist for good reasons.
What semaglutide actually is
Semaglutide is a GLP-1 receptor agonist — a synthetic analogue of the human incretin hormone GLP-1, with ~94% sequence homology to native GLP-1. The 2.4 mg weekly dose (Wegovy) is FDA-approved for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity. It is a prescription medication requiring physician evaluation before initiation.
Step 1: Determine Whether You Are a Candidate
FDA-approved indications for semaglutide 2.4 mg for chronic weight management include adults with BMI ≥30, or BMI ≥27 with at least one qualifying comorbidity (hypertension, type 2 diabetes, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease).
Key absolute contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and prior serious hypersensitivity to semaglutide. Pregnancy is a contraindication. Relative contraindications requiring clinical judgment include history of pancreatitis, significant gastroparesis, and gallbladder disease.
Important: Any platform that guarantees approval before reviewing your medical history is not operating under appropriate clinical standards. Prescriptions are never guaranteed — they are determined by a licensed physician who reviews your individual case.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Step 2: Choose a Licensed Platform
A legitimate platform will meet all of the following criteria:
- Employs or contracts with board-certified physicians licensed in your state
- Requires a complete health intake covering medications, medical history, and contraindications
- Does not guarantee prescriptions before clinical review
- Dispenses medication through a licensed pharmacy (503A, 503B, or retail)
- Provides ongoing clinical follow-up through dose escalation and beyond
To see verified programs filtered to your state and budget, use our free matching tool — it takes 60 seconds.
Step 3: Complete the Medical Intake Thoroughly
The asynchronous health questionnaire is doing real clinical work. A reviewing physician uses your answers to assess eligibility, screen for contraindications, and identify drug interactions. Complete it accurately — omitting relevant history removes the clinical safeguard that protects your safety.
A thorough intake covers: current height and weight, complete medication list, personal and family history of thyroid and pancreatic disease, cardiovascular history, history of eating disorders, and reproductive status for women of childbearing age.
Step 4: Physician Review and Prescription Decision
A licensed physician or NP reviews your intake and makes an independent prescribing determination. This review takes a few hours to 48 hours. If approved, the prescriber specifies the starting dose and escalation schedule — always beginning at 0.25 mg weekly, not the 2.4 mg maintenance dose.
The STEP 1 trial reported nausea in 44.2% of semaglutide participants versus 16.2% of placebo participants, predominantly during dose escalation.1 This is expected and transient. Patients should be counseled that nausea during escalation does not typically indicate a need to stop.
Step 5: Medication Delivery and Self-Administration
Compounded semaglutide arrives as a multi-dose vial requiring subcutaneous self-injection. Brand-name Wegovy arrives as pre-filled auto-injectors. Injection sites include the abdomen, outer thigh, and upper arm — rotated with each administration. Store at 36–46°F (2–8°C).
Step 6: Ongoing Monitoring — This Is Not Optional
The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of lost weight over the following 48 weeks.2 GLP-1 therapy is long-term disease management, not a short-term intervention. Meaningful clinical monitoring includes weight response assessment, cardiovascular risk factor monitoring, and gastrointestinal symptom evaluation at regular intervals.